BTI-322 for acute rejection after renal transplantation

Transplantation Proceedings

Volumn 29, Issue 5, 1997, Pages 2353-

  Mourad, M ^a   Besse, T ^a   Malaise, J ^a   Baldi, A ^a   Latinne, D ^a   Bazin, H ^a   Pirson, Y ^a   Hope, J ^b   Squifflet, J P ^a,c  

^a UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^b BioTransplant Inc   (United States)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; BTI 322; CREATININE; IMMUNOGLOBULIN G2B; LO CD2A; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEVER; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD2; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; RATS; TRANSPLANTATION, HOMOLOGOUS;

EID: 12644310313     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(97)00398-9     Document Type: Conference Paper

References (1)

1. Latinne D, De La Parra B, Nizet Y, et al: Int Immunol 8:1113, 1996